📊 STAA Key Takeaways
Is Staar Surgical Co (STAA) a Good Investment?
STAAR Surgical maintains a fortress balance sheet with 73.6% gross margins and zero debt, but faces significant operational headwinds with 23.7% revenue decline and persistent negative operating cash flow of -$21.7M despite positive net income. The gap between accounting profits and negative free cash flow, combined with a 295% EPS collapse, suggests structural challenges requiring operational stabilization before bullish reassessment.
Staar Surgical Co Key Strengths (STAA)
- Industry-leading gross margins of 73.6% indicating strong product pricing power and manufacturing efficiency
- Fortress balance sheet with $131.9M cash, zero long-term debt, and 5.12x current ratio providing substantial financial flexibility
- Ophthalmic medical device sector with essential product demand and recurring revenue characteristics
STAA Stock Risks: Staar Surgical Co Investment Risks
- Revenue declined 23.7% YoY with diluted EPS plummeting 295%, indicating severe market or competitive headwinds
- Operating cash flow of -$21.7M coupled with negative free cash flow despite $5.2M net income signals quality-of-earnings concerns and potential working capital deterioration
- Operating margin compression to 8.5% from substantially higher historical levels suggests fixed cost burden or pricing pressure not yet reflected in gross margins
Key Metrics to Watch
- Operating cash flow return to positive territory and free cash flow stabilization
- Revenue growth inflection and customer retention metrics to confirm downturn reversing
- Gross margin sustainability above 70% to ensure no deterioration in competitive position
Staar Surgical Co (STAA) Financial Metrics & Key Ratios
💡 AI Analyst Insight
Strong liquidity with a 5.12x current ratio provides a solid financial cushion.
STAA Profit Margin, ROE & Profitability Analysis
STAA vs Market Sector: How Staar Surgical Co Compares
How Staar Surgical Co compares to Market sector averages
Sector benchmarks are approximate industry averages. Actual sector performance may vary.
Is Staar Surgical Co Stock Overvalued? STAA Valuation Analysis 2026
Based on fundamental analysis, Staar Surgical Co has mixed fundamental signals relative to the Market sector in 2026.
Note: This is a fundamental analysis based on SEC filings. For P/E ratio, price targets, and market-based valuation, consult financial data providers. This is not investment advice.
Staar Surgical Co Balance Sheet: STAA Debt, Cash & Liquidity
STAA Revenue & Earnings Growth: 5-Year Financial Trend
5-Year Trend Summary: Staar Surgical Co's revenue has grown significantly by 40% over the 5-year period, indicating strong business expansion. The most recent EPS of $0.43 reflects profitable operations.
STAA Revenue Growth, EPS Growth & YoY Performance
STAA Quarterly Earnings & Performance
| Quarter | Revenue | Net Income | EPS |
|---|---|---|---|
| Q1 2026 | $42.6M | $5.2M | $0.10 |
| Q3 2025 | $88.6M | $8.9M | $0.18 |
| Q2 2025 | $44.3M | $4.0M | $0.08 |
| Q1 2025 | $42.6M | -$3.3M | $-0.07 |
| Q3 2024 | $80.3M | $4.8M | $0.10 |
| Q2 2024 | $92.3M | $4.0M | $0.08 |
| Q1 2024 | $73.5M | $2.7M | $0.05 |
| Q3 2023 | $76.0M | $4.8M | $0.10 |
Data sourced from SEC EDGAR 10-Q quarterly filings. Figures may represent quarterly or cumulative values.
Staar Surgical Co Dividends, Buybacks & Capital Allocation
STAA SEC Filings: Latest 10-K & 10-Q Analysis
Access official SEC EDGAR filings for Staar Surgical Co (CIK: 0000718937)
📋 Recent SEC Filings
❓ Frequently Asked Questions about STAA
What is the AI rating for STAA?
Staar Surgical Co (STAA) has an AI grade of B with 72% confidence, based on fundamental analysis of SEC EDGAR filings.
What are STAA's key strengths?
Claude: Industry-leading gross margins of 73.6% indicating strong product pricing power and manufacturing efficiency. Fortress balance sheet with $131.9M cash, zero long-term debt, and 5.12x current ratio providing substantial financial flexibility.
What are the risks of investing in STAA?
Claude: Revenue declined 23.7% YoY with diluted EPS plummeting 295%, indicating severe market or competitive headwinds. Operating cash flow of -$21.7M coupled with negative free cash flow despite $5.2M net income signals quality-of-earnings concerns and potential working capital deterioration.
What is STAA's revenue and growth?
Staar Surgical Co reported revenue of $93.5M.
Does STAA pay dividends?
Staar Surgical Co does not currently pay dividends.
Where can I find STAA SEC filings?
Official SEC filings for Staar Surgical Co (CIK: 0000718937) including 10-K, 10-Q, and 8-K reports are available on SEC EDGAR.
What is STAA's EPS?
Staar Surgical Co has a diluted EPS of $0.10.
How is the AI analysis conducted?
Two independent AI systems — Claude (Anthropic) and ChatGPT (OpenAI) — analyze SEC EDGAR filings including 10-K annual reports and 10-Q quarterly reports. Each AI evaluates financial health, profitability ratios, balance sheet strength, and growth metrics. The combined grade reflects both perspectives for balanced insights.
What is STAA's fundamental grade?
Based on our AI fundamental analysis in May 2026, Staar Surgical Co has a B grade with 72% confidence. Review the strengths and risks sections above for full context. This is not investment advice.
Is STAA stock overvalued or undervalued?
Valuation metrics for STAA: ROE of 1.5% (sector avg: 15%), net margin of 5.6% (sector avg: 12%). Compare these metrics with sector averages to assess valuation.
What is STAA's AI grade for 2026?
Our dual AI analysis gives Staar Surgical Co a combined B grade for 2026. Revenue is data pending, with profitability at or below sector average. Always conduct your own research.
What is STAA's free cash flow?
Staar Surgical Co's operating cash flow is $-21.7M, with capital expenditures of $443.0K. FCF margin is -23.7%.
How does STAA compare to other Market stocks?
Vs Default sector averages: Net margin 5.6% (avg: 12%), ROE 1.5% (avg: 15%), current ratio 5.12 (avg: 1.8).